Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe…
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of…
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
January 06, 2025 16:30 ET | Source: Generation Bio Co. Novel programs…
Partnership Established to Advance WHO’s Road Map for Neglected Tropical Diseases 2021-2030
TOKYO and GENEVA, Dec. 11, 2024 /PRNewswire/ -- The Global Health Innovative…
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company,…